Potter Barney I, Kondor Rebecca, Hadfield James, Huddleston John, Barnes John, Rowe Thomas, Guo Lizheng, Xu Xiyan, Neher Richard A, Bedford Trevor, Wentworth David E
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.
Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA 30333, USA.
Virus Evol. 2019 Dec 4;5(2):vez046. doi: 10.1093/ve/vez046. eCollection 2019 Jul.
The 2017-2018 North American influenza season caused more hospitalizations and deaths than any year since the 2009 H1N1 pandemic. The majority of recorded influenza infections were caused by A(H3N2) viruses, with most of the virus's North American diversity falling into the A2 clade. Within A2, we observe a subclade which we call A2/re that rose to comprise almost 70 per cent of A(H3N2) viruses circulating in North America by early 2018. Unlike most fast-growing clades, however, A2/re contains no amino acid substitutions in the hemagglutinin (HA) segment. Moreover, hemagglutination inhibition assays did not suggest substantial antigenic differences between A2/re viruses and viruses sampled during the 2016-2017 season. Rather, we observe that the A2/re clade was the result of a reassortment event that occurred in late 2016 or early 2017 and involved the combination of the HA and PB1 segments of an A2 virus with neuraminidase (NA) and other segments a virus from the clade A1b. The success of this clade shows the need for antigenic analysis that targets NA in addition to HA. Our results illustrate the potential for non-HA drivers of viral success and necessitate the need for more thorough tracking of full viral genomes to better understand the dynamics of influenza epidemics.
2017 - 2018年北美流感季导致的住院和死亡人数超过了自2009年甲型H1N1流感大流行以来的任何一年。记录的大多数流感感染是由A(H3N2)病毒引起的,该病毒在北美的大多数变异株属于A2进化枝。在A2进化枝中,我们观察到一个子进化枝,我们称之为A2/re,到2018年初,它在北美传播的A(H3N2)病毒中占近70%。然而,与大多数快速增长的进化枝不同,A2/re在血凝素(HA)片段中没有氨基酸替换。此外,血凝抑制试验并未表明A2/re病毒与2016 - 2017季采样的病毒之间存在显著的抗原差异。相反,我们观察到A2/re进化枝是2016年末或2017年初发生的一次重配事件的结果,该事件涉及一个A2病毒的HA和PB1片段与一个来自A1b进化枝病毒的神经氨酸酶(NA)及其他片段的组合。这个进化枝的成功表明除了HA之外,还需要针对NA进行抗原分析。我们的结果说明了病毒成功的非HA驱动因素的可能性,并且有必要更全面地追踪完整的病毒基因组,以更好地了解流感流行的动态。